prospective customers [0.1:5% of subjects on fenoldopam Event Placebo (n = 7) Fenoldopam (n = 125) n (%) n (%) Headache 1 (14%) 30 (24%) Nausea 0 15 (12%) Vomiting 0 7 (6%) Injection site reaction 0 9 (7%) Electrocardiogram T wave inversion 0 7 (6%) The following additional adverse reactions were observed more frequently in patients treated with fenoldopam Incidence 0.5% to 5% Metabolism and Nutrition Disorders Hypokalemia Psychiatric Disorders Nervousness/Anxiety, insomnia Nervous System Disorders Dizziness Cardiac Disorders Extrasystoles, palpitations, cardiac failure, ischemic heart disease, myocardial infarction, angina pectoris, tachycardia Gastrointestinal Disorders Abdominal pain Skin and Subcutaneous Tissue Disorders Hyperhidrosis Musculoskeletal and Connective Tissue Disorders Muscle spasms Renal and Urinary Disorders Oliguria General Disorders and Administration Site Conditions Chest pain, pyrexia Investigations Blood urea increased, blood creatinine increased, blood glucose increased, transaminases increased, blood lactate dehydrogenase increased Post-Marketing Experience The following adverse reactions have been identified during post approval use of Corlopam. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Voluntary reports of adverse reactions temporally associated with Corlopam that have been received since market introduction and that may have no causal relationship with the drug include the following: Cardiac Disorders Cardiogenic shock Vascular Disorders Hypotension Gastrointestinal Disorders Abdominal distension Investigations Electrocardiogram ST segment depression, oxygen saturation decreased Drug Interactions Beta-Blockers Avoid concomitant use of fenoldopam with beta-blockers. If the drugs are used together, blood pressure should be monitored frequently because hypotension could result from beta-blocker inhibition of the sympathetic reflex response to fenoldopam. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category B. Oral reproduction studies have been performed in rats and rabbits at doses of 12.5 to 200 mg/kg/day and 6.25 to 25 mg/kg/day, respectively. Studies have revealed maternal toxicity at the highest doses tested but no evidence of impaired fertility or harm to the fetus due to fenoldopam. There are, however, no adequate and well-controlled studies in pregnant women. Since animal reproduction studies are not always predictive of human response, fenoldopam should be used in pregnancy only if clearly needed. Nursing Mothers Fenoldopam is excreted in milk in rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, discontinue nursing or fenoldopam. Pediatric Use Safety and effectiveness of fenoldopam have been established in the age groups age] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer Pfizer Inc. Drug Class Agents for hypertensive emergencies Related Drugs agents for hypertensive emergencies nitroprusside , diazoxide , Nipride RTU , Nitropress , Proglycem , Hyperstat Hypertensive Emergency hydralazine , enalapril , nifedipine , labetalol , captopril , Vasotec , Apresoline , methyldopa , Capoten , Normodyne , Trandate , nitroprusside , More... Prevention of Radiographic Contrast Nephropathy fenoldopam , More... Corlopam Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! a really
prime Corlopam package
EmoticonEmoticon